Biogen Stays the Wrong Course After a Key Drug Failure

Bookmark
(Bloomberg Opinion) -- Biogen is by far the worst-performing large-cap biotech stock of 2019 after the March failure of its key Alzheimer’s drug pushed its shares down more than 20 percent. Its fi...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.